Pfizer pulls PAH drug Thelin from market after unpredictable deaths
This article was originally published in Scrip
Executive Summary
Pfizer has voluntarily pulled its pulmonary arterial hypertension (PAH) drug Thelin (sitaxentan) from the markets in which it is approved - the EU, Canada and Australia - and is discontinuing ongoing clinical studies after three drug-related deaths occurred, due to liver toxicity.